Pieris Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of Anticalin class of biotherapeutics for patients with diseases. The Company is focused on developing two drug candidates, PRS-080 and PRS-060. PRS-080 is an Anticalin protein that binds to hepcidin, a natural regulator of iron in the blood. PRS-080 has been designed to target hepcidin for the treatment of functional iron deficiency (FID), in anemic patients with chronic kidney disease (CKD), in end-stage renal disease patients requiring dialysis. PRS-060 is a drug candidate that binds to the IL-4RA receptor, thereby inhibiting IL-4 and IL-13, two cytokines, small proteins mediating signaling between cells within the human body, which are mediators in the inflammatory cascade that causes asthma and other inflammatory diseases. It is also developing PRS-110 in cMet-related cancer and PRS-300 series.